Joel Weinthal
About
In The Last Decade
Joel Weinthal
14 papers receiving 483 citations
Peers
Comparison fields: 5 of 66
- Hematology 166
- Genetics 143
- Molecular Biology 125
- Oncology 101
- Neurology 79
Countries citing papers authored by Joel Weinthal
This map shows the geographic impact of Joel Weinthal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Weinthal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Weinthal more than expected).
Fields of papers citing papers by Joel Weinthal
This network shows the impact of papers produced by Joel Weinthal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Weinthal. The network helps show where Joel Weinthal may publish in the future.
Co-authorship network of co-authors of Joel Weinthal
This figure shows the co-authorship network connecting the top 25 collaborators of Joel Weinthal. A scholar is included among the top collaborators of Joel Weinthal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Weinthal. Joel Weinthal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | Disease state awareness in Gaucher disease: a Q&A expert roundtable discussion. | 16 |
| 3 | 29 | |
| 4 | 0 | |
| 5 | 103 | |
| 6 | 86 | |
| 7 | 11 | |
| 8 | A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group. | 10 |
| 9 | 10 | |
| 10 | 6 | |
| 11 | 20 | |
| 12 | 70 | |
| 13 | Decreased endogenous circulating Steel factor (SLF) levels following allogeneic and autologous BMT: lack of an inverse correlation with post-BMT myeloid engraftment. | 17 |
| 14 | 42 | |
| 15 | Expression of human glucocerebrosidase following retroviral vector-mediated transduction of murine hematopoietic stem cells. | 26 |
| 16 | 50 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.